Adherence improvement in glaucoma patients

Completed

• Conditions: Glaucoma; ocular hypertension; 10018307

• Registration Number: NL-OMON31300
• Lead Sponsor: Alcon Laboratories

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 1000

Inclusion Criteria

Diagnosis glaucoma or ocular hypertension
Treatment with travoprost or travoprost/timolol

Exclusion Criteria

High risk of side effects expected from travoprost or travoprost/timolol
Absolute inability to administer eye drops
Difficulty in reading or speaking Dutch

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary endpoint is the intraocular pressure measured at the ophthalmologists<br /><br>office. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoints are the registration of adherence by the Travalert, the<br /><br>weight of the medication bottles, patient satisfaction and refill compliance in<br /><br>the next three years.</p><br>